Fri, 11th Dec 2020 09:12
Dec 11 (Reuters) - Britain's AstraZeneca on Friday
said that it will begin work with Russia's Gamaleya Institute to
understand whether their two COVID-19 vaccine candidates can be
successfully combined.
The Gamaleya Institute is the developer of Russia's Sputnik
V vaccine.
(Reporting by Pushkala Aripaka in Bengaluru; editing by Patrick
Graham)
(Correcting company name in headline)
(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsort...
(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out...
(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for pr...
(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood canc...
Astrazeneca (AZN)